Evelo Biosciences, Inc. (EVLO)

0,0495 +0,0020 (+4,21%) Alla chiusura: 02:32PM EDT

Evelo Biosciences, Inc.

620 Memorial Drive
5th Floor
Cambridge, MA 02139
United States
617 577 0300
https://www.evelobio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 66

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Craig R. Jalbert CIRA	President, Secretary, Principal Executive, Financial and Accounting Officer & Director	N/D	N/D	1962
Dr. Chun Zhang Ph.D.	Chief Technical Operations & Quality Officer	N/D	N/D	N/D
Dr. Mark Bodmer Ph.D.	Chief Scientific Officer and President of Research & Development	668,8k	N/D	1958
Ms. Jessica Cotrone	VP & Head of Communications	N/D	N/D	N/D
Ms. Leslie Wardwell-Scott Ph.D.	VP and Head of Corporate Development & Strategic Integration	N/D	N/D	N/D
Dr. Andrea Itano Ph.D.	Head of Research	N/D	N/D	N/D
Dr. Duncan McHale M.D., MBBS, Ph.D.	Chief Medical Officer	661,97k	N/D	1967
Mr. Douglas Maslin	Senior Director & Immunology Clinical Lead	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2017 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Evelo Biosciences, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.